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Human type II iodothyronine deiodinase (D2) catalyzes the
activation of T4 to T3. The D2 enzyme, like the type I (D1) and
type III (D3) deiodinases, contains a selenocysteine (SeC) res-
idue (residue 133 in D2) in the highly conserved catalytic
center. Remarkably, all of the D2 proteins cloned so far have
an alanine two residue-amino terminal to the SeC, whereas all
D1 and D3 proteins contain a cysteine at this position. A cys-
teine residue in the catalytic center could assist in enzymatic
action by providing a nucleophilic sulfide or by participating
in redox reactions with a cofactor or enzyme residues. We
have investigated whether D2 mutants with a cysteine
(A131C) or serine (A131S) two-residue amino terminal to the
SeC are enzymatically active and have characterized these
mutants with regard to substrate affinity, reducing cofactor
interaction and inhibitor profile.
COS cells were transfected with expression vectors encod-
ing wild-type (wt) D2, D2 A131C, or D2 A131S proteins. Kinetic
analysis was performed on homogenates with dithiothreitol
(DTT) as reducing cofactor. The D2 A131C and A131S mutants
displayed similar Michaelis-Menten constant values for T4 (5
nM) and reverse T3 (9 nM) as the wt D2 enzyme. The limiting
Michaelis-Menten constant for DTT of the D2 A131C enzyme
was 3-fold lower than that of the wt D2 enzyme. The wt and
mutant D2 enzymes are essentially insensitive to propylthio-
uracil [concentration inhibiting 50% of activity (IC50) > 2 mM]
in the presence of 20 mM DTT, but when tested in the presence
of 0.2 mM DTT the IC50 value for propylthiouracil is reduced
to about 0.1 mM. During incubations of intact COS cells ex-
pressing wt D2, D2 A131C, or D2 A131S, addition of increasing
amounts of unlabeled T4 resulted in the saturation of [
125I]T4
deiodination, as reflected in a decrease of [125I]T3 release into
the medium. Saturation first appeared at medium T4 concen-
trations between 1 and 10 nM.
In conclusion: substitution of cysteine for a conserved ala-
nine residue in the catalytic center of the D2 protein does not
inactivate the enzyme in vitro and in situ, but rather improves
the interaction with the reducing cofactor DTT in vitro. (En-
docrinology 143: 1190–1198, 2002)
T4, THE MAIN secretory product of the thyroid gland,undergoes enzymatic outer ring deiodination (ORD) in
peripheral tissues to T3 catalyzed by the deiodinases type I
(D1) and type II (D2) (1–3). The D1 protein (4–7) has a high
Michaelis-Menten constant (Km) for T4 (5 m), is activated
by dithiothreitol (DTT) in vitro, and is highly sensitive to
inhibition by propylthiouracil (PTU) in vitro and in vivo. The
D2 protein has a low Km for T4 (5 nm), is also activated by
DTT but is only minimally sensitive to PTU (8–10). The
catalytic mechanism, though incompletely described, seems
to be different between D1 and D2. ORD of T4 by D1 protein
exhibits ping-pong (bi)-substrate kinetics with T4 and the
thiol-containing cofactor as cosubstrates (6, 8, 11, 12). The D2
protein exhibits sequential reaction kinetics, suggesting that
T4 and the thiol-containing cofactor must interact with the
enzyme simultaneously before reaction takes place (8, 9).
Another remarkable difference between D1 and D2 is the fact
that while N-bromoacetyl derivatives of T4 or T3 are excellent
covalent affinity labels of D1, they do not label the D2 sel-
enoprotein (13–16).
The D1 protein is a selenoenzyme, containing a seleno-
cysteine (SeC) residue in the catalytic center (4, 17, 18). This
SeC residue is essential for enzymatic activity because re-
placement with leucine or alanine eliminates deiodinase ac-
tivity, whereas replacement with cysteine reduces the turn-
over number about 100-fold (19, 20). The SeC in the catalytic
center of D1 is thought to function as the iodine acceptor and
PTU probably inhibits D1 via the formation of a SeC-PTU
adduct (6, 12, 19). The inability to covalently label D2 with
bromoacetyl-iodothyronine derivatives, as well as the dras-
tically reduced sensitivity to PTU, iodoacetate, and gold thio-
glucose compared with D1, have been interpreted as evi-
dence that deiodination by D2 does not require the
participation of enzyme sulfydryl groups (21) or that D2 is
not a selenoprotein (19, 22). The inability to label the
substrate-binding subunit of D2 (p29) in rat glial cells with
75Se was also interpreted as evidence that D2 is not a sel-
enoprotein (23). However, since the cloning of D2 cDNAs
from several species and the identification of SeC insertion
sequence elements (SECIS) in the 3-UTR, it is clear that the
D2 protein is a selenoenzyme containing a SeC residue in
the catalytic center (10, 16, 24–29). More direct evidence for
the selenoprotein character of D2 protein was recently pro-
vided by the demonstration that a 75Se-labeled protein of the
expected size is immunoprecipitated from mesothelioma
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cells with a D2 antiserum (30). Therefore, the described dif-
ferences between D1 and D2 must be influenced by other
factor(s) than the presence of SeC in the catalytic center.
The core catalytic center of D1 and D2 is located in a region
about 15 amino acids long, surrounding the essential SeC. This
region is highly conserved within and between the D1 and D2
subtype enzymes (Fig. 1). However, all of the D2 proteins
cloned so far have an alanine two residues amino-terminal to
the SeC, whereas all D1 proteins contain a cysteine (Cys) at this
position (1–3, 29). A Cys residue in the catalytic center could
assist in enzymatic action by providing a nucleophilic sulfide or
by participating in redox reactions with a cofactor or enzyme
residues. Replacement of Cys by alanine (Ala) in the active
center of D1 caused a marked increase in the limiting Km for
DTT (11, 31). By analogy, the absence of a Cys residue at the
same position (residue 131) in human D2 might reduce the
turnover number compared with D1 and could perhaps explain
the minimal sensitivity of D2 to PTU or the inability to react
with bromoacetyl derivatives of T3 and T4.
The present studies were performed to elucidate the func-
tional consequences of the absence of a Cys residue in the
catalytic center of human D2 protein. We have examined
effects of the Ala131 to Cys (A131C) mutation either alone or
in combination with a SeC133 to Cys mutation (SeC133C/
A131C) on substrate affinity, reducing cofactor interaction
and inhibitor profile.
Materials and Methods
Materials
Nonradioactive iodothyronines were obtained from Henning Berlin
GmbH & Co. (Berlin, Germany) and [3, 5-125I]T4 (specific activity 969
Ci/mmol) was obtained from NEN Life Science Products (Boston, MA).
[3, 5-125I]reverse T3 (rT3) was prepared by radioiodination of 3,3-T2
using the chloramine-T method as described (32). Before each experi-
ment, the radiolabeled iodothyronines were purified on Sephadex
LH-20 columns (33). Radioactively labeled N-bromoacetyl-T4 or N-
bromoacetyl-T3 were synthesized from bromoacetylchloride and [
125I]T4
or [125I]T3 as described (13).
PTU (6-n-propyl-2-thiouracil), gold thioglucose (GTG), and iodoac-
etate (IAc) were obtained from Sigma (St. Louis, MO). DTT was obtained
from ICN Biochemicals, Inc. (Costa Mesa, CA). Recombinant Taq DNA-
polymerase was obtained from Amersham Pharmacia Biotech
(Roosendaal, The Netherlands) and synthetic oligonucleotides were or-
dered from Life Technologies, Inc. (Glasgow, UK).
Site-directed mutagenesis and construction of
expression vectors
A cDNA clone containing the entire coding sequence of the human
D2 protein was used for mutagenesis via the overlap extension DNA-
polymerase reaction procedure (34).
Overlapping inner sense and antisense primers containing the nu-
cleotide changes needed to produce the SeC133Cys (SeC133C) D2 mu-
tant cDNA, Ala131Cys (A131C) D2 mutant cDNA, Ala131Ser (A131S) D2
mutant cDNA, and SeC133Cys/Ala131Cys (double Cys) D2 mutant
cDNA were used for amplification with a Kozak start consensus (un-
derlined) 5-outer primer (5-CAAGCTTGCCACCATGGGCATCCT-
CAGCGTA) or a stop 3-outer primer (5-CAAGCTTTTAACCAGCTA-
ATCTAGT), each containing flanking HindIII restriction sites (italics).
The PCR products were agarose gel purified and used for overlap
extension PCR reactions with the described outer primers. The mutated
D2 cDNA fragments were subcloned into the pGEM-T vector (Promega
Corp., Madison, WI) and sequenced to confirm that only the proper
mutations were introduced. Because a SECIS element is required for
incorporation of SeC in selenoproteins, we prepared chimeric constructs
in which the D2 cDNA was inserted 5 to the SECIS element of the rat
D1 gene. For this purpose, the G21-pcDNA3 rat D1 expression vector (4)
was digested with HindIII, and the 6-kb DNA band containing vector
DNA plus 0.7 kb of the rat D1 3-UTR (including the SECIS element) was
isolated from a preparative agarose gel. The pGEM vectors containing
the respective mutant D2 sequences were digested with HindIII, and the
isolated fragments were cloned into the prepared rat D1-SECIS-pcDNA3
vector. A wt human D2 expression vector was prepared in the same
manner. It should be noted that the 3-(second) TGA, which is seven
codons 5 to the universal stop codon TAA in the D2 cDNA, is present
in all constructs. It is not known how efficient the second UGA codon
is translated as SeC.
Expression of D2 protein
The wt D2 and mutant D2 enzymes were expressed in COS-1 cells
after diethylaminoethyl-dextran-mediated transfection of the expres-
sion vectors (35). COS-1 cells were grown in DMEM-Ham’s F-12 me-
dium (DMEM/F12) containing 10% FCS (Life Technologies, Inc.) and 40
nm Na2SeO3. One day before transfection, cells were divided 1:10 in
90-mm diameter culture dishes. Expression constructs (8 g per dish),
isolated by alkaline lysis and polyethyleneglycol precipitation (36), were
added to 5 ml serum-free DMEM/F12 medium containing 200 g/ml
diethylaminoethyl-dextran. After 2 h, the medium was replaced by
serum-free DMEM/F12 containing 100 m chloroquine phosphate (Sig-
ma). Again, 2 h later the medium was replaced with DMEM/F12 con-
taining 10% FCS and 40 nm Na2SeO3. After 2 d, the cells were rinsed with
PBS and collected in 0.25 ml 0.1 m phosphate (pH 7.2), 2 mm EDTA
buffer, sonicated, aliquoted, and stored at 75 C.
Assay of ORD activity in COS cell homogenates
The principle of this assay is the production of radioiodide by ORD
of [3, 5-125I]T4 or [3, 5-
125I]rT3. Duplicate incubations contained about
100,000 cpm labeled T4 or rT3 with varying amounts of unlabeled sub-
strate (T4 or rT3) and COS cell homogenates (50–100g protein) in a final
volume of 0.2 ml P100E2D20 buffer (0.1 m sodium phosphate; 2 mm
EDTA; 20 mm DTT, pH 7.2). In some experiments, the DTT concentration
was varied between 0.1 and 20 mm DTT. In various experiments, the
inhibitors PTU (0.1–2 mm), GTG (0.1–3 m), and BrAcT4 (0.1–1000 nm)
were included. Mixtures were incubated for 60 min at 37 C, whereafter
the reaction was stopped by the addition of 0.1 ml 5% BSA on ice.
Protein-bound iodothyronines were subsequently precipitated by 10%
TCA on ice, and the radioiodide in the supernatant was separated from
remaining iodothyronines by chromatography on Sephadex LH-20 mini
columns as described (33). The fractions were counted for 125I-activity
in a 16 channel -counter (NE1600, Nuclear Enterprises, Edinburgh, UK).
Enzymatic deiodination was corrected for nonenzymatic deiodina-
tion in blank incubations with homogenates of nontransfected COS cells
( 3% of total deiodination). Protein was adjusted to consume less than
30% of substrate, and in control experiments it was determined that the
deiodination rate was linear up to 60 min incubation. The radioiodide
production counted was multiplied by 2 to account for the random
labeling and deiodination at the 3 and 5 positions in the substrate. By
reverse-phase HPLC of reaction products, it was established that equal
amounts of radioiodide and radioactive iodothyronine (T3 or T2) were
produced. No inner-ring deiodination was detected with wt or D2 mu-
tant enzymes.
FIG. 1. Deduced amino acid sequences comprising the core catalytic
center of the three iodothyronine deiodinases. All D2 enzymes cloned
so far (human, mouse, rat, chicken, Xenopus, Rana, trout) have an Ala
two residues amino-terminal to the SeC, while all D1 and D3 proteins
contain a Cys at this position.
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Assay of ORD activity in intact transfected COS cells
COS cells were cultured in 6-well plates and transfected with 2.5 g
plasmid per well as described. One day after transfection, cell mono-
layers were washed with serum-free DMEM/F12 medium and then
cultured for an additional 24 h in serum-free DMEM/F12 (plus 40 nm
Na2SeO3), to which was added [
125I]T4 (1 10
6 cpm/ml) plus 1–1000 nm
unlabeled T4.
Medium was harvested and extracted with ice-cold methanol (1:1).
After centrifugation, the extract was mixed with 0.02 m ammonium
acetate (pH 4) and 0.1 ml of the mixture was applied to a 250  4.6 mm
Symmetry C18 column connected to an Alliance HPLC system (Waters
Chromatography Division, Millipore Corp., Milford, MA), and eluted
with a 20-min gradient of 24–29% acetonitrile followed by a 6-min
gradient of 29–50% acetonitrile in 0.02 m ammonium acetate (pH 4) at
a flow rate of 1.2 ml/min. Radioactivity in the eluate was monitored on
line using a Radiomatic A-500 flow scintillation detector (Packard, Me-
riden, CT). The percentage T4 deiodination was calculated from the
amount of [125I]T3 produced (multiplied by two), divided by the amount
of [125I]T4 added.
Incubation with N-bromoacetyl-[125I]T3 or T4
Labeling of COS cell homogenates was done according to previously
published procedures (14). In short, solutions of BrAc[125I]T3 or
BrAc[125I]T4 (150,000 cpm) in ethanol were pipetted into microcentrifuge
tubes, and the solvent was evaporated by a stream of nitrogen. After
addition of 25 l P100E2D3 [100 mm sodium phosphate; 2 mm EDTA;
3 mm DTT, pH 7.2], and vortexing, the COS cell homogenates (150 g
protein) were added in a total volume of 50 l P100E2D3. Again the
mixtures were vortexed and incubated at 37 C for 20 min. Reactions were
terminated by the addition of gel-loading buffer, and samples were
analyzed by SDS-PAGE (12% gel) followed by autoradiography (14).
For in situ affinity labeling experiments, COS cells were transfected
with wt D2, D2 A131C, or rat D1 expression vectors, and 1 d after
transfection cells were washed and than cultured for an additional 24 h
in serum-free DMEM/F12, to which was added BrAc[125I]T4 (200,000
cpm/ml equivalent to 0.25 nm). The medium was harvested and ana-
lyzed by HPLC as described. The cells were collected in 0.25 ml 0.1 m
phosphate (pH 7.2), 2 mm EDTA buffer, sonicated, and samples were
analyzed by SDS-PAGE.
Results
Analysis of mutant D2 enzymes in vitro
To define the effects of the introduction of a Cys residue
in the catalytic center of D2, expression vectors were made
encoding mutant D2 enzymes with a Cys (D2 A131C) or Ser
(D2 A131S) two-residue amino terminal to the SeC. A Cys at
this position (as in D1 and D3) could assist in enzymatic
action by providing a nucleophilic sulfide or by participating
in redox reactions with cofactor or enzyme residues. Serine
was chosen as a control because it is most homologous to Cys,
and it is unlikely that the side chain hydroxyl group partic-
ipates in redox reactions. In another set of mutants, the SeC
residue was substituted by Cys (essentially exchanging Se by
S), thus creating the D2 SeC133C mutant enzyme and the D2
SeC133C/A131C double mutant enzyme.
COS cells were transfected with the described expression
vectors and kinetic analysis was performed on homogenates
in the presence of 20 mm DTT (Fig. 2 and Table 1). The
wild-type D2, D2 A131C, and D2 A131S enzymes displayed
similar Km values for T4 (5 nm) as well as for rT3 (9 nm).
Remarkably, substituting Cys for SeCys caused a 1,000-fold
higher Km for the substrate T4 and a 10-fold higher Vmax
compared with wt D2 protein. The same holds true for the
double Cys mutant (D2 SeC133C/A131C) enzyme. Coincu-
bations with up to 250 m selenocystine (which is converted
to selenocysteine in the presence of DTT) did not further
increase the deiodination rate of the D2 SeC133C enzyme
(not shown).
We performed Western blotting of COS cell homogenates
with polyclonal antisera directed against the C terminus or
the catalytic center of the rat D2 protein (37). Only in ho-
mogenates containing D2SeC133C or D2SeC133C/A131C
protein, a specific band of the expected molecular mass (31
kDa) could be detected (not shown).
The D2 protein exhibits sequential reaction kinetics, and
Lineweaver-Burk plots at different reducing cofactor (DTT)
concentrations yield a set of intersecting lines (8, 9). To in-
vestigate the possibility that introduction of a Cys in the
catalytic center influences the interaction with reducing co-
factor, T4 ORD was studied at several concentrations of DTT.
The transfected COS cells were harvested in phosphate
buffer (pH 7.2) without DTT, and without addition of DTT
the net deiodination of T4 was less than 0.5% in 60 min. In
initial experiments, the T4 concentration was fixed (2 nm) and
the DTT concentration was varied over a broad range (0.1–30
mm). At the lowest DTT concentrations (0.1 and 0.3 mm), the
deiodination rate of the D2 A131C enzyme was higher com-
pared with the D2 A131S and D2 wt enzymes (Fig. 3). In more
detailed studies, both DTT (0.1–1 mm) and T4 (1–10 nm)
FIG. 2. Lineweaver-Burk plots of T4 deiodination catalyzed by wt D2,
D2 A131C, D2 A131S enzymes (A) and by D2 SeC133C or D2
SeC133C/A131C enzyme (B). Each data point is the average of closely
agreeing duplicate determinations, and the experiment was per-
formed twice on different homogenates with similar results.
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concentrations were varied. The Lineweaver-Burk plots were
derived at each DTT concentration for the wt D2 and D2
A131C enzyme (Fig. 4, A and B, respectively). The plots
consisted of a set of intersecting lines, implying that the
sequential mechanism of deiodination is not altered by the
introduction of a Cys residue in the catalytic center. A replot
of the reciprocal of the apparent Vmax values obtained against
the reciprocal of the DTT concentrations yielded the limiting
Km for DTT. The limiting Km DTT for the D2 A131C enzyme
was 3-fold lower than that of the wt D2 enzyme (0.10 mm 
0.03 vs. 0.37 mm 0.15, respectively, mean sem, n 3). The
lower limiting Km DTT of the D2 A131C enzyme would
predict a higher Vmax compared with wt D2 enzyme at a DTT
concentration of 0.1 mm, provided that the expression levels
are equal (Fig. 5). Indeed, under these conditions the Vmax of
the D2 A131C enzyme was higher compared with the wt D2
enzyme (0.10 pmol/minmg vs. 0.06 pmol/minmg), whereas
the Km for T4 was similar (0.7 nm).
The cofactor dependence of the SeC133Cys D2 enzyme
was also investigated. At a T4 concentration of 2 m, the
deiodination rate of the D2 SeC133C and D2 SeC133C/
A131C enzymes increased with increasing DTT concentra-
tion and reached an optimum at 3 mm DTT (not shown). The
deiodination rate of the D2 SeC133C/A131C enzyme was
similar at the optimal DTT concentration to that of the D2
SeC133C enzyme. Therefore, the increased deiodination rate
of the A131C mutant at low DTT concentrations is only
detectable for D2 proteins with a SeC residue in the catalytic
center.
DTT is a potent but nonphysiological reducing cofactor for
D2 (8, 9). The monothiol glutathione (GSH) might be a phys-
iological cofactor for D2. However, neither the wt D2, the D2
A131C, nor the D2 A131S enzymes are activated by GSH
(range 0.1–25 mm tested) in vitro (not shown).
To compare the PTU sensitivity of the wt D2, D2 A131C,
and D2 A131S enzymes, the deiodination of T4 was studied
in the presence of different concentrations of the reducing
cofactor DTT because it has been shown that PTU inhibits D2
activity in brown adipose tissue homogenates at low DTT
(5 mm DTT) concentrations (9). In the presence of 20 mm
DTT, no significant inhibition by PTU was observed
(Fig. 6A). However, in the presence of 0.2 mm DTT the
enzyme activity was about 70% inhibited by 1 mm PTU for
the wt D2, D2 A131C, and D2 A131S enzymes (Fig. 6A). In
the presence of 0.2 mm DTT, the wt D2 and D2 A131S en-
zymes are about 40% as active as in the presence of 20 mm
TABLE 1. Kinetic characteristics of D2 enzymes (incubations in presence of 20 mM DTT)
Deiodinase Km (T4)
Vmax (T4)
pmol T4/minmg
Km (rT3)
Vmax (rT3)
pmol rT3/minmg
D2 wt 4.9  0.7 nM 0.48  0.12 8.9 nM 0.14
D2 A131C 4.5  0.5 nM 0.25  0.08 9.8 nM 0.11
D2 A131S 5.4  1.1 nM 0.49  0.17 10.1 nM 0.15
D2 SeC133C 5.0 M 5.4
D2 SeC133C/A131C 6.6 M 4.1
FIG. 3. Lineweaver-Burk plots of T4 deiodination catalyzed by wt D2,
D2 A131C, or D2 A131S enzymes at a single concentration of T4 (2 nM)
in the presence of varying concentrations of DTT (0.1–30 mM).
FIG. 4. Double-reciprocal plots of the rate of T4 deiodination by wt D2
(A) or D2 A131C (B) enzyme as a function of T4 concentration at 0.1
mM DTT, 0.3 mM DTT, or 1.0 mM DTT. Each data point is the average
of closely agreeing duplicate determinations, and the experiment was
performed twice with similar results.
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DTT, whereas the D2 A131C enzyme is about 70% as active
as in the presence of 20 mm DTT. We have not investigated
the inhibitory mechanism but it is unlikely that the inhibition
is caused by a reaction of (oxidized) PTU with DTT because
even at a PTU concentration of 2 mm, the inhibition was not
complete.
Apart from PTU, GTG and IAc were also tested. GTG is a
noncompetitive inhibitor of native D2 protein (16, 38). No
significant change in sensitivity for GTG (Fig. 6B) of the D2
A131C and D2 A131S enzymes in comparison with wt D2
could be detected (IC50  0.7 m). IAc is a weak inhibitor of
native D2 (IC50  1000 m) but a strong inhibitor of native
D1 (IC50  2 m), which has a Cys in the catalytic center (21,
39). However, the sensitivity of D2 for IAc was not increased
by the introduction of a Cys residue in the catalytic center.
For both the wt D2 and D2 A131C enzymes, the IC50
was greater than 1000 m (not shown).
Wild-type D2, D2 A131C, and D2 A131S proteins are not
covalently labeled by N-bromoacetyl-[125I]T3 or
N-bromoacetyl-[125I]T4
When homogenates from COS cells expressing wt D2, D2
A131C, or D2 A131S protein were incubated with
BrAc[125I]T3 or BrAc[
125I]T4, the labeling patterns obtained
after SDS-PAGE were identical with those obtained using
homogenates of nontransfected COS cells (not shown). Un-
der identical experimental conditions, labeling patterns of
homogenates from COS cells expressing rat D1 protein
showed an additional labeled band of 29 kDa corresponding
to the D1 protein (not shown). Analysis by SDS-PAGE
of labeling patterns from in situ labeled COS cells revealed
labeling of the rat D1 protein (5 d autoradiography),
but no labeling of wt D2 or D2 A131C protein. More than 90%
of the added radioactivity was recovered in the medium, and
by HPLC analysis it was found that almost all BrAc[125I]T3
was converted to more polar compound(s). This conversion
was not further investigated, but it may reflect reaction with
free amino acids or GSH.
Despite the fact that BrAcT4 does not bind covalently to D2
protein, it does inhibit T4 deiodination of wt D2, D2 A131C,
and D2 A131S enzymes (Fig. 6C). The inhibition is complete
at 100 nm BrAcT4, and the IC50 is about 0.5 nm.
Deiodination by wild-type D2, Ala131Cys, and Ala131Ser
D2 mutants in intact cells
The D2 A131C and D2 A131S enzymes are active in vitro
in the presence of the cofactor DTT. An important question
is if the same is true under in situ conditions using intact
transfected cells, in which the availability of T4 and/or co-
factor activity may be more restricted.
FIG. 5. Lineweaver-Burk plots of T4 deiodination catalyzed by wt D2
or D2 A131C enzymes at a single concentration of DTT (0.1 mM) in the
presence of different T4 concentrations.
FIG. 6. Effect of PTU, GTG, or BrAcT4 on T4 deiodination by wt D2
(), D2 A131C (‚) or D2 A131S (E) enzymes. A, Inhibition of T4 (2 nM)
deiodination by wt D2, D2 A131C or D2 A131S enzymes by PTU in
the presence of 0.2 mM DTT, but in the presence of 20 mM DTT the
wt D2, D2 A131C or D2 A131S enzymes are insensitive to PTU. B,
Inhibition of T4 (2 nM) deiodination by wt D2, D2 A131C or D2 A131S
enzymes by GTG. C, Inhibition of T4 (2 nM) deiodination by wt D2, D2
A131C, or D2 A131S enzymes by BrAcT4.
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When wt D2 was expressed in COS cells, addition of in-
creasing amounts of unlabeled T4 resulted in the saturation
of [125I]T4 deiodination, as reflected in a decrease of [
125I]T3
release into the medium (Fig. 7). Saturation first appeared at
medium total T4 concentrations between 1 and 10 nm (the
radiolabeled T4 contributes about 0.5 nm). In control exper-
iments using [125I]T4, it was established that nontransfected
COS cells contain no deiodinase activity nor sulfotransferase
activity. When the D2 A131C and D2 A131S enzymes were
studied in the same manner, there was a similar progressive
decrease in the fractional deiodination of [125I]T4, thus indi-
cating that the D2 mutants are active under in situ conditions
(Fig. 7).
Discussion
The aim of the present study was to investigate whether
the absence of a Cys residue in the catalytic center of D2
protein might explain the reduced sensitivity to PTU and/or
the inability to covalently label D2 with BrAc-iodothyronine
derivatives. Moreover, we wanted to investigate whether the
D2 A131C enzyme would still be active in vivo and in vitro.
Indeed, the D2 A131C protein is enzymatically active. The
most striking finding was the reduced limiting Km for the
cosubstrate DTT of the D2 A131C enzyme, whereas the Km
values for the substrates T4 and rT3 were similar to those of
wt D2. The rather low Km for DTT of the wt D2, D2 A131C,
and D2 A131S enzymes are perhaps surprising given the fact
that typical D2 assays are usually done in the presence of 20
mm DTT. In many instances, D2 assays are done on micro-
somal fractions, and under those conditions the limiting Km
for DTT is greater than 10 mm (1, 8). Using brown adipose
tissue homogenates, Goswami et al. (9) reported a limiting Km
DTT of 0.5 mm for D2, which is in line with our results using
COS cell homogenates. The Km values for T4 and rT3 (5 nm
and 9 nm, respectively) determined in the presence of 20 mm
DTT are in agreement with previously reported values using
homogenates of transfected cells (10, 16, 25). In the presence
of 0.1 mm DTT, the Km for T4 is reduced to 0.7 nm, which is
inherent to the sequential reaction kinetics of the D2 enzyme.
The Vmax of D2 A131C enzyme is about 2-fold lower than
that of wt D2 and D2 A131S enzymes, when tested in the
presence of 20 mm DTT (Table 1). We performed semiquan-
titative Western blotting of COS cell homogenates with poly-
clonal antisera directed against the C terminus or the cata-
lytic center of rat D2 protein (37). Unfortunately, only in
homogenates containing D2 SeC133C or D2 SeC133C/A131C
protein, a specific band with the expected molecular mass (31
kDa) could be detected (not shown). It was shown before,
using different antisera, that the expression level of the hu-
man D2 SeC133C protein is about 100-fold higher than that
of wt D2 protein in transfected cells (38). The wt D2 and D2
A131C protein levels in COS cell homogenates are too low
and/or the cross-reactivity of the rat D2 antisera with human
D2 protein is not strong enough. Consequently, we cannot
answer the question whether the 2-fold lower Vmax of the D2
A131C enzyme is due to reduced protein levels or reduced
catalytic efficiency in the presence of 20 mm DTT. Remark-
ably, when tested in the presence of 0.1 mm DTT, the Vmax
of D2 A131C enzyme is 2-fold higher compared with wt D2.
It has been shown that modest changes in deiodination ki-
netics resulting from mutations in the catalytic center of D1
enzyme were not apparent when the same mutant constructs
were tested in intact cell systems (31). On the other hand, the
large (1,000-fold) increase in the Km for T4 due to the re-
placement of SeC133 by Cys in D2 was reflected in assays
with intact transfected cells (38). In our experiments, the
modest increase in Vmax of the D2 A131C enzyme compared
with the wt D2 enzyme in the presence of 0.1 mm DTT was
not reflected in the intact cell system. Limitations in the rate
of cellular T4 uptake or endogenous cofactor availability
could restrict the rate of deiodination and thus negate a
difference in the activities of the D2 enzymes. It is clear,
however, that introduction of a Cys residue in the catalytic
center of D2 protein does not impair catalytic activity in vitro
and in situ.
The D1 protein is strongly inhibited by PTU (IC50 5 m),
GTG (IC50  0.05 m), and IAc (IC50  2 m), and this was
initially explained by the presence of a reactive SH group in
the enzyme-active center (6–8). When D1 protein was iden-
tified as a selenoprotein, it was proposed that the SeC residue
reacts in the reduced (SeH) form with IAc and GTG, whereas
the selenenyl iodide (SeI) intermediate is the target for in-
hibition by PTU (19, 39). The D2 enzyme also contains a SeC
residue in the catalytic center but is much less sensitive to
inhibition by PTU (IC50  1000 m), GTG (IC50  1 m) and
IAc (IC50  1,000 m) when tested in the presence of 20 mm
DTT. Only when tested in the presence of 0.2 mm DTT, the
D2 enzyme becomes more sensitive to PTU. Introduction of
a cysteine residue in the catalytic center (D2 A131C), as is the
case in D1, did not significantly increase the sensitivity of D2
for PTU, GTG, or IAc. This suggests that the wt D2 and D2
A131C enzymes use a different mechanism of deiodination
than D1. This conclusion is supported further by the fact that
both the wt and D2 A131C enzymes appear to follow se-
quential reaction kinetics, whereas D1 follows ping-pong
kinetics (8, 11, 19, 39).
Remarkably, substituting Cys for SeCys133 caused a 1,000-
fold higher Km for the substrate T4 (Table 1), in line with
previously published data (38). The same holds true for the
double Cys mutant (D2 SeC133C/A131C) protein. In con-
FIG. 7. In situ deiodination at varying T4 concentrations. COS cells
were transfected with wt D2, D2 A131C, or D2 A131S expression
vectors, and 24 h posttransfection intact cell deiodination was deter-
mined as described in Materials and Methods.
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trast, substitution of Cys for SeCys in D1 caused a modest 5-
to 10-fold increase in the Km for ORD of rT3 and T4 (20).
We propose a model in which the SeC residue in D2 exerts
a nucleophilic attack to the 2-position of T4, thus forming a
bond between the SeC residue and T4 (Fig. 8). Subsequent
steps involve the abstraction of iodonium (I	) by DTT (or
another thiol group containing cofactor), providing a D2T3
complex and a cofactor sulfenyl iodide. The latter will rap-
idly disproportionate to iodide (I) and oxidized thiol,
whereas the enzyme intermediate will yield T3 and the un-
modified enzyme. The reaction as a whole requires two thiol
groups, which could be supplied by one DTT molecule. In
this model, the activated substrate is directly reduced by the
cofactor, whereas in the case of D1 the SeI intermediate is
reduced by cofactor (6, 8, 11, 21). In the case of the D2 A131C
enzyme, an additional pathway is possible in which the
iodonium is transferred to the SH group of Cys 131, followed
by reduction of the SI intermediate by DTT.
This model of reductive dehalogenation has been de-
scribed for the reductive dehalogenation of 5-bromo- and
5-iodo-2-deoxyuridylate by thymidylate synthetase (40–42)
and was, among other models, discussed for the ORD of T4
(43). In thymidylate synthetase, Cys residue 198 attacks the
C6 position of the pyrimidine in bromo-deoxyuridine mono-
phosphate, and the Km for this reductive dehalogenation
reaction is about 26m (42). The D2 SeC133C mutant enzyme
is active, suggesting that also in D2 a correctly positioned Cys
residue is able to attack the substrate. However, the SH group
is a much weaker nucleophile than the SeH group, thus
explaining the 1,000-fold increased Km value and the 10-fold
reduced turnover number. Also in other seleno-enzymes, as
for instance thioredoxin reductase and formate dehydroge-
nase, exchanging Se for S reduces the catalytic turnover num-
ber up to 100-fold (44, 45). Interestingly, addition of seleno-
cystine and thioredoxin partially restored the strongly
reduced peroxidase activity of the SeC498C mutant thiore-
doxin reductase enzyme (44). However, addition of seleno-
cystine did not further increase the deiodination rate of T4 by
the D2 SeC133C protein.
In D1, the SeI intermediate is the target for inhibition by
PTU (6, 12, 19, 39, 43). According to our model, such an
intermediate does not exist in D2, thus explaining the in-
sensitivity for PTU of D2. Only under suboptimal conditions
causing reduced deiodination rates, i.e. at low (0.2 mm DTT)
reducing cofactor concentrations, the wt D2 and D2 mutant
enzymes become sensitive to PTU, although the inhibition is
never complete. Under these suboptimal conditions (oxi-
dized) PTU might compete with substrate for reaction with
the selenol group. Obviously, this is less favored than reac-
tion with the selenenyl iodide intermediate in D1 explaining
the much higher concentrations of PTU needed. The pro-
posed model also explains why the D2 A131C mutant en-
zyme is not more sensitive to PTU because the D2 A131C
enzyme has in fact a higher deiodination rate at low DTT
concentrations.
The PTU sensitivity of D2 enzyme at low (and perhaps
physiologically more relevant) thiol cofactor concentrations
as demonstrated in this and previous studies (9, 46), poses
questions with regard to the extent to which D1 and D2 are
inhibited in vivo by PTU. Certainly because D1 inhibition by
PTU is dependent on turnover (formation of SeI intermedi-
ate), which might be limited at physiological T4 concentra-
tions. On the other hand, PTU is taken up in organs that
express D1 (liver, kidney), whereas it is not or poorly taken
up in several D2-expressing tissues such as brain and brown
adipose tissue (46). In line with this, kinetic analysis of cir-
culating T3 in PTU-blocked rats has suggested significant T3
production from T4 by D2 enzyme (47).
The proposed catalytic model might form the basis for the
design of transition state analogs that specifically inhibit D2.
For instance, brominated analogs of T4 may still bind to D2
and react with the selenol group but may be blocked in
bromonium abstraction. Such analogs would permanently
block the catalytic site and could in fact also be used as D2
affinity labels.
A bit puzzling still is the low susceptibility of D2 to IAc and
GTG. It has been suggested that the reactivity of the selenol
group in D2 is much less than that in D1 (39), implying a
lower turnover number of D2 enzyme. At the moment, it is
not possible to investigate this hypothesis because we have
no way to determine the D2 enzyme turnover number. The
inhibition by GTG of D2 is noncompetitive with substrate,
whereas it is competitive with substrate for D1 (22, 38). The
interaction with GTG might therefore occur with a Cys res-
idue outside the catalytic center of D2. An alternative ex-
planation may be that in D1 the modification of the selenol
group by GTG or IAc is irreversible, whereas in D2 it is
reversible, at least for IAc, because T4 also forms a covalent
complex with the selenol group.
A remarkable difference between D1 and D2 protein is the
fact that while N-bromoacetyl derivatives of T4 and T3 are
excellent affinity labels of D1, they do not label D2 protein
(13–16). In principle, not only SeC but also cysteine, tyrosine,
histidine, lysine, and arginine residues may be modified by
bromoacetyl reagents (48). After introduction of a Cys res-
idue in the catalytic center of D2, as in D2 A131C, it is still
not possible to obtain affinity labeling with BrAcT4 or
FIG. 8. Model of catalysis by D2 enzyme. We propose a model in which
the SeC residue exerts a nucleophilic attack to the 2-position of T4,
thus forming a bond between the SeC residue and T4. This model could
explain the 1,000-fold increased Km value for T4 of the D2 SeC133C
enzyme, and the low sensitivity to PTU of D2 compared with D1
enzyme.
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BrAcT3. Attempts to develop an in situ affinity labeling sys-
tem for D2 protein with BrAc-T3 were also unsuccessful.
These experiments were based on observations that some
proteins, as for instance steroid receptors, are labeled more
efficiently with affinity ligands in situ than in homogenates
(49). Meanwhile, BrAcT4 does covalently label the 29 kDa
substrate-binding subunit, p29, of D2 in rat brain cells (50).
The p29 protein is not a selenoprotein (51), and its relation-
ship to the 31-kDa D2 selenodeiodinase used in this study is
uncertain. The observed strong inhibition by BrAcT4 of wt D2
and mutant D2 enzymes is in line with previous observations
that BrAcT3 inhibits D2 activity (52) and that alanine side
chain modified analogs of T4 inhibit D2 activity in glial cell
sonicates (53).
It has been known for long that D2 activity is rapidly
down-regulated by T4 via a posttranscriptional mechanism
that increases the rate of degradation or inactivation of the
enzyme (53–58). It was recently proposed that this substrate-
induced loss of D2 activity is due to proteasomal degradation
of the enzyme and requires substrate interaction with the
catalytic center (58). In other words, the catalytic center must
be modified in some way by substrate in order for the ubiq-
uitination machinery to be able to recognize D2 protein. The
intermediate complexes formed between the SeC residue and
the substrates T4 or rT3 proposed in our catalytic model, may
fulfill that role.
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